Consortium Therapeutic Studies of Primary Central Nervous System Malignancies

原发性中枢神经系统恶性肿瘤联合治疗研究

• 批准号: 7341058
• 负责人: TIMOTHY CLOUGHESY
• 金额: $ 14.66万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-05-14 至 2008-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7341058
• 关键词: Acceleration; Adult; Angiogenesis Inhibitors; Biological Response Modifier Therapy; Brain Neoplasms; California; Cancer Center; Cancer Therapy Evaluation Program; Central Nervous System Neoplasms; Clinic; Clinical; Clinical Research; Clinical Trials; Community Clinical Oncology Program; Computers and Advanced Instrumentation; Cytotoxic agent; Data; Databases; Development; Doctor of Medicine; Drug Controls; Drug Kinetics; Environment; Evaluation; Funding; Genes; Glioblastoma; Glioma; Goals; Grant; Guidelines; Human; Immune; Industry; Institution; Intramural Research Program; Investigation; Laboratory Finding; Laboratory Study; Lead; Los Angeles; Malignant Glioma; Malignant Neoplasms; Malignant neoplasm of brain; Memorial Sloan-Kettering Cancer Center; Modality; Molecular Genetics; Neuraxis; New Agents; New Approaches to Brain Tumor Therapy Consortium; Newly Diagnosed; North American Brain Tumor Consortium; Operative Surgical Procedures; Outcome; Patients; Pediatric Brain Tumor Consortium; Phase; Physicians; Population; Procedures; Protocols documentation; Purpose; Quality Control; Quality of life; Radiation enhancer; Radiosurgery; Recurrence; Reproduction spores; Research; Research Infrastructure; Research Personnel; Resources; San Francisco; Signal Transduction Inhibitor; Specimen; Standards of Weights and Measures; System; Techniques; Texas; Therapeutic Agents; Therapeutic Studies; Translational Research; Tumor Biology; United States Food and Drug Administration; United States National Institutes of Health; Universities; Wisconsin; Work; concept; data management; design; improved; innovation; interdisciplinary approach; member; neuro-oncology; neuroimaging; novel; novel strategies; novel therapeutics; programs; protocol development; research clinical testing; tumor

DESCRIPTION (provided by applicant): UCLA Neuro-Oncology Program will participate in the clinical trials of the North American Brain Tumor Consortium (NABTC) as a "Member Institution". Member Institutions of the NABTC will also include, the University of Wisconsin, the University of Pittsburgh, Dana Farber Cancer Center, M D Anderson Cancer Center, the Neuro-Oncology Branch at the National Institutes of Health, the University of California, San Francisco, Memorial Sloan Kettering Cancer Center and the Pharmacokinetics Center at the University of Texas San Antonio. UCSF will be the Lead Institution and Dr. Prados the Group Leader for the NABTC. The focus of this grant will be to perform phase I and II clinical evaluations of promising new therapeutic agents or approaches for the treatment of primary CNS malignancies in adult patients, especially glioblastoma multiforme and other high grade gliomas. Additionally, we will perform ancillary laboratory studies of aspects of CNS tumor biology with potential clinical implications. UCLA will continue to extend it ongoing work with NABTC by interacting with other members of the consortium and with NCI in a concerted way to conceive, create and evaluate new approaches to the therapy of CNS tumors. This will be largely achieved through the existing environment and expertise that exist at UCLA including physician investigators, multidisciplinary approach, data management resources, patient population, expertise and advanced instrumentation for neuroimaging, surgery and radiation, and drug control procedures. UCLA will also provide an effective environment and expertise for multi-institutional protocol concept development and protocol conduct. Finally, significant infrastructure expertise exists at UCLA to aide the consortium with needs that are important for the acceleration of brain cancer translational research.

描述（由申请人提供）：UCLA神经肿瘤学项目将作为“成员机构”参加北美脑肿瘤联盟（NABTC）的临床试验。NABTC的成员机构还包括威斯康星大学、匹兹堡大学、达纳法伯癌症中心、MD安德森癌症中心、美国国立卫生研究院神经肿瘤分支、加州大学弗朗西斯科分校、纪念斯隆凯特琳癌症中心和德克萨斯大学圣安东尼奥分校药代动力学中心。UCSF将成为NABTC的领导机构，Prados博士将成为NABTC的组长。该资助的重点将是对有前途的新治疗药物或方法进行I期和II期临床评价，用于治疗成人患者的原发性CNS恶性肿瘤，特别是多形性胶质母细胞瘤和其他高级别胶质瘤。此外，我们还将对具有潜在临床意义的CNS肿瘤生物学方面进行辅助实验室研究。加州大学洛杉矶分校将继续通过与联盟的其他成员和NCI以协调一致的方式进行互动来扩展其与NABTC正在进行的工作，以构思，创建和评估CNS肿瘤治疗的新方法。这将在很大程度上通过UCLA现有的环境和专业知识来实现，包括医生研究人员，多学科方法，数据管理资源，患者人群，神经成像，手术和放射的专业知识和先进仪器，以及药物控制程序。加州大学洛杉矶分校还将提供一个有效的环境和专业知识的多机构协议的概念开发和协议的行为。最后，加州大学洛杉矶分校拥有重要的基础设施专业知识，以帮助该联盟满足对加速脑癌转化研究至关重要的需求。